To fill this gap, the aim of the present study was to characterize the frequency of DPYD *2A, *13, c.2846T>A, HapB3, and *6 alleles in Greek cancer patients treated with the FPs 5-FU or CAP and to further analyze their association with FP-induced (severe) toxicity and dose intensity. The gene discussed is DPYD; the disease is cancer.